WuXi Biologics (Cayman) 관리
관리 기준 확인 2/4
WuXi Biologics (Cayman) CEO는 Chris Chen, Jan2016 에 임명되었습니다 의 임기는 8.83 년입니다. 총 연간 보상은 CN¥ 96.91M, 4.1% 로 구성됩니다. 4.1% 급여 및 95.9% 보너스(회사 주식 및 옵션 포함). 는 HK$ 208.62M 가치에 해당하는 회사 주식의 0.35% 직접 소유합니다. 208.62M. 경영진과 이사회의 평균 재임 기간은 각각 2.6 년과 7.2 년입니다.
주요 정보
Chris Chen
최고 경영자
CN¥96.9m
총 보상
| CEO 급여 비율 | 4.1% |
| CEO 임기 | 8.8yrs |
| CEO 소유권 | 0.4% |
| 경영진 평균 재임 기간 | 2.6yrs |
| 이사회 평균 재임 기간 | 7.2yrs |
최근 관리 업데이트
Recent updates
After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar
Sep 26
WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet
Sep 12Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why
Jun 12Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%
Jun 11Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding
Jun 11Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥3b |
| Mar 31 2024 | n/a | n/a | CN¥3b |
| Dec 31 2023 | CN¥97m | CN¥4m | CN¥3b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥4b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥79m | CN¥3m | CN¥4b |
| Sep 30 2022 | n/a | n/a | CN¥4b |
| Jun 30 2022 | n/a | n/a | CN¥4b |
| Mar 31 2022 | n/a | n/a | CN¥4b |
| Dec 31 2021 | CN¥51m | CN¥3m | CN¥3b |
| Sep 30 2021 | n/a | n/a | CN¥3b |
| Jun 30 2021 | n/a | n/a | CN¥3b |
| Mar 31 2021 | n/a | n/a | CN¥2b |
| Dec 31 2020 | CN¥31m | CN¥3m | CN¥2b |
| Sep 30 2020 | n/a | n/a | CN¥1b |
| Jun 30 2020 | n/a | n/a | CN¥1b |
| Mar 31 2020 | n/a | n/a | CN¥1b |
| Dec 31 2019 | CN¥25m | CN¥3m | CN¥1b |
| Sep 30 2019 | n/a | n/a | CN¥922m |
| Jun 30 2019 | n/a | n/a | CN¥831m |
| Mar 31 2019 | n/a | n/a | CN¥731m |
| Dec 31 2018 | CN¥20m | CN¥2m | CN¥631m |
| Sep 30 2018 | n/a | n/a | CN¥520m |
| Jun 30 2018 | n/a | n/a | CN¥410m |
| Mar 31 2018 | n/a | n/a | CN¥331m |
| Dec 31 2017 | CN¥24m | CN¥2m | CN¥253m |
보상 대 시장: Chris 의 총 보상 ($USD 13.37M )은 Hong Kong 시장( $USD 887.42K ).
보상과 수익: Chris 의 보상은 작년에 20% 이상 증가한 반면 회사 수익은 20% 이상 감소했습니다.
CEO
Chris Chen (51 yo)
8.8yrs
테뉴어
CN¥96,911,000
보상
Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Founder & Chairman | 10.8yrs | 데이터 없음 | 데이터 없음 | |
| CEO & Executive Director | 8.8yrs | CN¥96.91m | 0.35% HK$ 208.6m | |
| Honorary President of Global Biologics Development | 9.6yrs | CN¥32.89m | 0.013% HK$ 8.0m | |
| CFO & Executive VP | 3yrs | 데이터 없음 | 데이터 없음 | |
| COO & Senior VP | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Technology Officer and Executive VP of Global Biologics Development Department | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Scientific Officer & President of Global Biologics Research | no data | 데이터 없음 | 데이터 없음 | |
| Senior VP & Head of Investor Relations | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Compliance Officer | 2.2yrs | 데이터 없음 | 데이터 없음 | |
| VP & Head of Global Human Resources | no data | 데이터 없음 | 데이터 없음 | |
| Senior VP and Head of Global BD & Alliance Management | no data | 데이터 없음 | 데이터 없음 | |
| Chief Digital Officer | 4.8yrs | 데이터 없음 | 데이터 없음 |
2.6yrs
평균 재임 기간
56.5yo
평균 연령
경험이 풍부한 관리: 2269 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Founder & Chairman | 10.8yrs | 데이터 없음 | 데이터 없음 | |
| CEO & Executive Director | 10.8yrs | CN¥96.91m | 0.35% HK$ 208.6m | |
| Honorary President of Global Biologics Development | 8.5yrs | CN¥32.89m | 0.013% HK$ 8.0m | |
| Independent Non-Executive Director | 1.5yrs | CN¥710.00k | 0.00063% HK$ 372.4k | |
| Member of Scientific Advisory Board | 6.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 6.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 6.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 6.8yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 7.5yrs | CN¥906.00k | 0.00053% HK$ 313.3k | |
| Non-Executive Director | 8.5yrs | 데이터 없음 | 데이터 없음 | |
| Non-Executive Director | 8.5yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 4.4yrs | CN¥933.00k | 0.0050% HK$ 2.9m |
7.2yrs
평균 재임 기간
59.5yo
평균 연령
경험이 풍부한 이사회: 2269 의 이사회는 경험(평균 재직 기간 7.2 년)으로 간주됩니다.